NCT02598427: Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer |
|
|
| Terminated | 1 | 1 | US | Pertuzumab, Perjeta, Trastuzumab, Herceptin | Kimberly Blackwell | HER2 Positive Untreated Metastatic Breast Cancer, Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer | 02/18 | 02/18 | | |
